Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals PLC Confident in ability to deliver long-term, sustainable growth

Hikma Pharmaceuticals PLC (LON: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI: 549300BNS685UXH4JI75) (rated Ba1 Moody’s / BB+ S&P, both stable), the multinational pharmaceutical group, will hold its Annual General Meeting today and provide an update on recent trading. Siggi Olafsson, Hikma’s CEO, said: “We are pleased to be holding our Annual General Meeting today, which will include a review of …

Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals PLC launches 100th injectable medicine in US

Hikma Pharmaceuticals PLC  (LON: HIK) (NASDAQ : HIK) (OTC: HKMPY) the multinational pharmaceutical company, today launched its 100th injectable medicine in the United States with the introduction of Vancomycin Hydrochloride for Injection, USP, 5g, 10g and 750mg, through its US affiliate, Hikma Pharmaceuticals USA Inc.1 “Vancomycin Hydrochloride for Injection is an essential antibiotic used by hospitals to treat patients who …

Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals PLC partnership with Melinta in MEN

Hikma Pharmaceuticals PLC (LON: HIK) (NASDAQ Dubai: HIK)(OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable) announced an exclusive license, supply and distribution agreement with Melinta Therapeutics (Melinta), for Melinta’s intravenous and oral formulations of Baxdela™ (delafloxacin) across all its MENA markets. In addition, Hikma has the right of first negotiation for all other products in Melinta’s portfolio and …

Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals PLC launches Mitomycin for Injection

Hikma Pharmaceuticals PLC (LON: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable) announced that Hikma Pharmaceuticals USA Inc., formerly known as West-Ward Pharmaceuticals Corp., has launched Mitomycin for Injection, USP, 20mg and 40mg. Hikma’s Mitomycin for Injection, USP is not recommended as single-agent, primary therapy. It has been shown to be useful in the …